[
  {
    "ts": null,
    "headline": "Cencora Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "summary": "Cencora Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=4582e83e6b03f0303401ee0b1b39a6157b08ebe236ef076ec195e889a62d16f4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1730998380,
      "headline": "Cencora Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "id": 131202094,
      "image": "",
      "related": "COR",
      "source": "MarketWatch",
      "summary": "Cencora Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=4582e83e6b03f0303401ee0b1b39a6157b08ebe236ef076ec195e889a62d16f4"
    }
  },
  {
    "ts": null,
    "headline": "Cencora Reports Strong Revenue and EPS Growth in 2024",
    "summary": "Cencora ( (COR) ) just unveiled an update. Cencora, Inc. reported significant growth in its fiscal 2024 results, boasting a 14.7% increase in fourth-quarter revenue to $79.1 billion and a 12.1% rise for the year to $294.0 billion. Despite a drop in GAAP diluted EPS to $0.02 in the fourth quarter, adjusted EPS saw a robust 16.8% rise to $3.34. The company enhanced its strategic pharmaceutical distribution capabilities and expanded its specialty services with the acquisition of Retina Consultants",
    "url": "https://finnhub.io/api/news?id=5f8e24fd532bf7a888f84c355f00b3f9ddcf705987d5385718d3fba453b59e53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1730980903,
      "headline": "Cencora Reports Strong Revenue and EPS Growth in 2024",
      "id": 131174469,
      "image": "https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2",
      "related": "COR",
      "source": "Yahoo",
      "summary": "Cencora ( (COR) ) just unveiled an update. Cencora, Inc. reported significant growth in its fiscal 2024 results, boasting a 14.7% increase in fourth-quarter revenue to $79.1 billion and a 12.1% rise for the year to $294.0 billion. Despite a drop in GAAP diluted EPS to $0.02 in the fourth quarter, adjusted EPS saw a robust 16.8% rise to $3.34. The company enhanced its strategic pharmaceutical distribution capabilities and expanded its specialty services with the acquisition of Retina Consultants",
      "url": "https://finnhub.io/api/news?id=5f8e24fd532bf7a888f84c355f00b3f9ddcf705987d5385718d3fba453b59e53"
    }
  },
  {
    "ts": null,
    "headline": "Cencora to acquire Retina Consultants of America for $4.6B in cash",
    "summary": "Cencora (COR) announced that it has entered into a definitive agreement to acquire Retina Consultants of America, a management services organization of retina specialists, from Webster Equity Partners. Cencora will acquire RCA for approximately $4.6B in cash, subject to a customary working capital and net-debt adjustment. RCA’s affiliated practices, physicians and management will retain a minority interest in RCA, with Cencora holding approximately 85% ownership in RCA upon closing. Additionally",
    "url": "https://finnhub.io/api/news?id=8db7aab7c8d34dfd71ad13a7aee1a14125ae55a2d3c078b9fcfcb082534f34eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1730979360,
      "headline": "Cencora to acquire Retina Consultants of America for $4.6B in cash",
      "id": 131174471,
      "image": "https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607",
      "related": "COR",
      "source": "Yahoo",
      "summary": "Cencora (COR) announced that it has entered into a definitive agreement to acquire Retina Consultants of America, a management services organization of retina specialists, from Webster Equity Partners. Cencora will acquire RCA for approximately $4.6B in cash, subject to a customary working capital and net-debt adjustment. RCA’s affiliated practices, physicians and management will retain a minority interest in RCA, with Cencora holding approximately 85% ownership in RCA upon closing. Additionally",
      "url": "https://finnhub.io/api/news?id=8db7aab7c8d34dfd71ad13a7aee1a14125ae55a2d3c078b9fcfcb082534f34eb"
    }
  }
]